IBOV 171,031.73 ▲ 1.85% IPSA 11,338.38 ▲ 0.89% IPC MEX 65,729.18 ▲ 2.14% MERVAL 2,913,184 ▲ 1.30% COLCAP 2,459.23 ▲ 0.61% BVL PERÚ 58,698.13 ▲ 2.60% USD/BRL5.14▲ 0.02% USD/MXN16.92▲ 0.07% USD/CLP914.28— 0.00% USD/COP3,043— 0.00% USD/PEN3.36▲ 0.05% USD/ARS1,499▼ 0.03% USD/UYU40.20— 0.00% USD/PYG5,996— 0.00% USD/BOB11.43— 0.00% USD/DOP58.61▼ 0.07% USD/CRC450.05— 0.00% USD/GTQ7.62— 0.00% USD/HNL26.81▲ 1.55% USD/NIO36.62— 0.00% USD/VES782.70▲ 0.48% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD 157.28 — 0.00% USD/TTD6.71— 0.00% EUR/BRL6.00▼ 0.03% BRENT 88.88 ▼ 0.03% WTI 83.11 ▼ 0.11% IRON ORE 161.91 — — COPPER 6.61 ▲ 0.03% GOLD 4,461 ▲ 1.78% SILVER 65.59 ▲ 1.26% SOY 1,184 ▲ 3.20% CORN 480.50 ▲ 10.02% WHEAT 655.00 ▲ 3.93% COFFEE 317.25 ▼ 5.51% SUGAR 16.43 ▼ 1.79% ORANGE JUICE 138.55 ▼ 0.47% COTTON 85.03 ▲ 2.33% COCOA 5,719 ▲ 3.18% BEEF 223.60 ▼ 3.93% CATTLE 339.10 ▼ 3.16% LITHIUM 75.20 ▲ 1.47% PETR4 41.64 ▼ 0.05% VALE3 72.97 ▲ 0.83% ITUB4 38.60 ▼ 1.03% BBDC4 16.85 ▲ 0.36% ABEV3 14.89 ▼ 0.80% BBAS3 19.37 ▲ 0.47% B3SA3 14.26 ▼ 0.21% WEGE3 47.59 ▲ 0.49% PRIO3 59.14 ▼ 0.19% SUZB3 41.33 ▲ 2.35% RENT3 34.68 ▼ 0.09% AZZA3 15.89 ▼ 2.63% CSAN3 3.22 ▼ 1.83% RAIZ4 0.25 — 0.00% PCAR3 2.75 ▼ 0.36% GMAT3 3.65 ▼ 1.08% PSSA3 48.13 ▼ 0.54% CVCB3 1.33 ▼ 2.92% POSI3 3.36 ▲ 2.44% SLCE3 13.34 ▲ 0.30% NATU3 8.14 ▼ 0.73% IBOV 171,031.73 ▲ 1.85% IPSA 11,338.38 ▲ 0.89% IPC MEX 65,729.18 ▲ 2.14% MERVAL 2,913,184 ▲ 1.30% COLCAP 2,459.23 ▲ 0.61% BVL PERÚ 58,698.13 ▲ 2.60% USD/BRL 5.16 ▲ 0.01% USD/MXN 17.06 ▼ 0.24% USD/CLP 913.98 ▲ 0.04% USD/COP 3,140 ▲ 0.03% USD/PEN 3.36 ▼ 0.66% USD/ARS 1,493 ▲ 0.10% USD/UYU 40.27 ▲ 1.24% USD/PYG 5,939 ▲ 1.68% USD/BOB 11.64 ▼ 0.76% USD/DOP 58.34 ▲ 1.25% USD/CRC 445.92 ▲ 0.89% USD/GTQ 7.62 ▲ 2.21% USD/HNL 26.79 ▲ 1.57% USD/NIO 36.62 ▲ 0.69% USD/VES 762.44 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.28 — 0.00% USD/TTD 6.70 ▲ 0.61% EUR/BRL 5.95 ▲ 1.01% BRENT 88.88 ▼ 0.03% WTI 83.11 ▼ 0.11% IRON ORE 161.91 — — COPPER 6.61 ▲ 0.03% GOLD 4,461 ▲ 1.78% SILVER 65.59 ▲ 1.26% SOY 1,184 ▲ 3.20% CORN 480.50 ▲ 10.02% WHEAT 655.00 ▲ 3.93% COFFEE 317.25 ▼ 5.51% SUGAR 16.43 ▼ 1.79% ORANGE JUICE 138.55 ▼ 0.47% COTTON 85.03 ▲ 2.33% COCOA 5,719 ▲ 3.18% BEEF 223.60 ▼ 3.93% CATTLE 339.10 ▼ 3.16% LITHIUM 75.20 ▲ 1.47% PETR4 41.64 ▼ 0.05% VALE3 72.97 ▲ 0.83% ITUB4 38.60 ▼ 1.03% BBDC4 16.85 ▲ 0.36% ABEV3 14.89 ▼ 0.80% BBAS3 19.37 ▲ 0.47% B3SA3 14.26 ▼ 0.21% WEGE3 47.59 ▲ 0.49% PRIO3 59.14 ▼ 0.19% SUZB3 41.33 ▲ 2.35% RENT3 34.68 ▼ 0.09% AZZA3 15.89 ▼ 2.63% CSAN3 3.22 ▼ 1.83% RAIZ4 0.25 — 0.00% PCAR3 2.75 ▼ 0.36% GMAT3 3.65 ▼ 1.08% PSSA3 48.13 ▼ 0.54% CVCB3 1.33 ▼ 2.92% POSI3 3.36 ▲ 2.44% SLCE3 13.34 ▲ 0.30% NATU3 8.14 ▼ 0.73%
since 2009
Monday, August 24, 2026

Latest News Life & Society

AIDS Drugs Cure Coronavirus Patient in Spain

By · March 1, 2020 · 3 min read

Daily Brief

The morning intel from across Latin America. Free.

By subscribing you agree to our privacy policy. We never share your email.

RIO DE JANEIRO, BRAZIL – The application of lopinavir/ritonavir, also used to fight HIV infections, along with interferon beta, a protein that helps cells protect themselves from infection, confirmed medical sources to EL PAÍS.

“It’s an experimental course of treatment that has yielded positive results against other viruses,” explains Albert Bosch, president of the Spanish Society of Virology. “One of its greatest advantages is that it is an approved drug used in other indications, so there is no question about its safety,” he adds.

An experimental treatment, based on the most widely used drugs to treat AIDS for more than a decade, was the chosen option by the doctors at the Hospital Virgen del Rocío in Seville (southern Spain) to successfully treat the first patient contaminated in Spain with the SARS-CoV-2 coronavirus.
An experimental treatment, based on the most widely used drugs to treat AIDS for more than a decade, was the chosen option by the doctors at the Hospital Virgen del Rocío in Seville (southern Spain) to successfully treat the first patient contaminated in Spain with the SARS-CoV-2 coronavirus. (Photo internet reproduction)
One-stop reference
Company Intelligence
Every listed company in Latin America — financials, ownership and structure for 1,450+ companies across 26 exchanges, in one place.
Browse the directory →
RT
Ask Rio Times
17 years of Latin America reporting, on demand.
Open the full Ask Rio Times →

One of these treatment-prone viruses is the one that causes Middle Eastern Respiratory Syndrome (MERS).

Although a recent publication in Nature magazine recalled that “there are no approved treatments for MERS,” Saudi-Arabia -the country most affected by this disease- is promoting clinical studies in humans. “The results are promising, but there is still not enough evidence for their approval, and they are in an experimental stage,” said the experts consulted.

Santiago Moreno, head of infectious diseases at the Hospital Ramón y Cajal (Madrid), explains that “the protease of SARS-CoV-2 is very similar to that of HIV,” and that “this enzyme is crucial for the virus to replicate itself. “The combination of lopinavir and ritonavir inhibits and blocks HIV,” he adds. “The results we know so far about its use against the Covid-19 (coronavirus) are encouraging,” he says.

The interferon beta, the other drug used in Seville, is similar in action. It is one of the so-called signaling proteins naturally produced by human cells when infected by a virus. “The aim is to alert the other cells, which thus develop a greater resistance to infection”, explains Bosch.

Some hospitals in Wuhan have also employed the treatment used in Virgen del Rocío in patients with the Coronavirus (Covid-19), according to several reports published in scientific journals, although again “there is little evidence about its effectiveness,” according to experts.

The combination of lopinavir and ritonavir inhibits and blocks HIV," he adds. "The results we know so far about its use against the Covid-19 (coronavirus) are encouraging," he says.
The combination of lopinavir and ritonavir inhibits and blocks HIV,” he adds. “The results we know so far about its use against the Covid-19 (coronavirus) are encouraging,” he says. (Photo internet reproduction)

The use of lopinavir/ritonavir along with interferon beta is one of the so-called treatments for “experimental use” approved by the Spanish Ministry of Health. These are therapies that can be requested when there are no therapeutic alternatives available, usually in serious or potentially fatal diseases. Doctors who think it may be useful for a particular patient must obtain written authorization to administer it from both the patient and the health authorities.

The successful results obtained at the Virgen do Rocío Hospital in this 62-year-old patient are remarkable due to the recent surge of Covid-19 and because it offers new clinical evidence. However, as is the case in medicine, an isolated case does not necessarily imply that it can be used in other patients, nor that the result will be the same. That is the task of clinical testing.

Source: El Pais

This article was produced by The Rio Times’ automated newsroom system. How we use AI · Report an error

Read More from The Rio Times

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.